



**HAL**  
open science

## Identification of 5-lipoxygenase and microsomal prostaglandin E synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol

Andreas Koeberle, Hinnak Northoff, Oliver Werz

### ► To cite this version:

Andreas Koeberle, Hinnak Northoff, Oliver Werz. Identification of 5-lipoxygenase and microsomal prostaglandin E synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol. *Biochemical Pharmacology*, 2009, 77 (9), pp.1513. 10.1016/j.bcp.2009.02.005 . hal-00493492

**HAL Id: hal-00493492**

**<https://hal.science/hal-00493492>**

Submitted on 19 Jun 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## Accepted Manuscript

Title: Identification of 5-lipoxygenase and microsomal prostaglandin E<sub>2</sub> synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol

Authors: Andreas Koeberle, Hinnak Northoff, Oliver Werz



PII: S0006-2952(09)00105-1  
DOI: doi:10.1016/j.bcp.2009.02.005  
Reference: BCP 10084

To appear in: *BCP*

Received date: 9-12-2008  
Revised date: 27-1-2009  
Accepted date: 11-2-2009

Please cite this article as: Koeberle A, Northoff H, Werz O, Identification of 5-lipoxygenase and microsomal prostaglandin E<sub>2</sub> synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.02.005

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Identification of 5-lipoxygenase and microsomal prostaglandin E<sub>2</sub> synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol**

**Running title:** Garcinol inhibits 5-lipoxygenase and mPGES-1

Andreas Koeberle<sup>a</sup>, Hinnak Northoff<sup>b</sup>, and Oliver Werz<sup>c\*</sup>

<sup>a</sup> Department for Pharmaceutical Analytics, Pharmaceutical Institute, University of Tuebingen, Auf der Morgenstelle 8, D-72076 Tuebingen, Germany

<sup>b</sup> Institute for Clinical and Experimental Transfusion Medicine, University Medical Center Tuebingen, Hoppe-Seyler-Straße 3, 72076 Tuebingen, Germany

\* **Corresponding author:** Dr. Oliver Werz, Department for Pharmaceutical Analytics, Pharmaceutical Institute, University of Tuebingen, Auf der Morgenstelle 8, D-72076 Tuebingen, Germany. Phone: +4970712978793; Fax: +497071294565; e-mail: [oliver.werz@uni-tuebingen.de](mailto:oliver.werz@uni-tuebingen.de)

**Abstract**

1  
2  
3  
4  
5 Garcinol (camboginol) from the fruit rind of Guttiferae species shows anti-carcinogenic and  
6  
7 anti-inflammatory properties, but the underlying molecular mechanisms are unclear. Here we  
8  
9 show that garcinol potently interferes with 5-lipoxygenase (EC 7.13.11.34) and microsomal  
10  
11 prostaglandin (PG)E<sub>2</sub> synthase (mPGES)-1 (EC 5.3.99.3), enzymes that play pivotal roles in  
12  
13 inflammation and tumorigenesis. In cell-free assays, garcinol inhibited the activity of purified  
14  
15 5-lipoxygenase and blocked the mPGES-1-mediated conversion of PGH<sub>2</sub> to PGE<sub>2</sub> with IC<sub>50</sub>  
16  
17 values of 0.1 and 0.3 μM, respectively. Garcinol suppressed 5-lipoxygenase product  
18  
19 formation also in intact human neutrophils and reduced PGE<sub>2</sub> formation in interleukin-1β-  
20  
21 stimulated A549 human lung carcinoma cells as well as in human whole blood stimulated by  
22  
23 lipopolysaccharide. Moreover, garcinol interfered with isolated cyclooxygenase (COX)-1 (EC  
24  
25 1.14.99.1, IC<sub>50</sub> = 12 μM) and with the formation of COX-1-derived 12(S)-hydroxy-5-cis-  
26  
27 8,10-trans-heptadecatrienoic acid and thromboxane B<sub>2</sub> in human platelets. In contrast, neither  
28  
29 Ca<sup>2+</sup>-ionophore (A23187)-induced arachidonic acid release in neutrophils nor COX-2 activity  
30  
31 in A549 cells or whole blood, measured as formation of 6-keto PGF<sub>1α</sub>, or isolated human  
32  
33 recombinant COX-2 were significantly affected by garcinol (≤ 30 μM). Together, the high  
34  
35 potency of garcinol to selectively suppress PGE<sub>2</sub> synthesis and 5-lipoxygenase product  
36  
37 formation provides a molecular basis for the anti-inflammatory and anti-carcinogenic effects  
38  
39 of garcinol and rationalizes its therapeutic use.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Abbreviations used:** AA, arachidonic acid; COX, cyclooxygenase; cPL, cytosolic phospholipase; ERK, extracellular signal-regulated kinase; FLAP, 5-lipoxygenase-activating protein; 12-HHT, 12(*S*)-hydroxy-5-cis-8,10-trans-heptadecatrienoic acid; iNOS, inducible nitric oxide synthase; 5-LO, 5-lipoxygenase; LT, leukotriene; mPGES, microsomal prostaglandin E<sub>2</sub> synthase; NSAIDs, non steroidal anti-inflammatory drugs; PG, prostaglandin.

## 1. Introduction

1  
2  
3  
4  
5 Garcinol (**Fig. 1A**) is a polyprenylated acylphloroglucinole contained in the rind of Guttiferae  
6  
7 (*Garcinia indica*, *G. huillkensis* and *G. cambogia*), named Kokum, which is used as culinary  
8  
9 spice and garnish for curry. In India, Kokum is used in ayurvedic medicine for the treatment  
10  
11 of inflammatory and infectious diseases [1]. In rats, garcinol protects against 4-nitroquinoline-  
12  
13 1-oxide-induced tongue carcinogenesis [2] and azoxymethane-induced colon carcinogenesis  
14  
15 [3]. Functional investigations have revealed anti-oxidative [4], anti-proliferative [5], pro-  
16  
17 apoptotic [6], anti-invasive [7], and anti-inflammatory properties of garcinol [6, 8, 9].  
18  
19 Garcinol reduced the expression or activation of kinases involved in cell proliferation (i.e.,  
20  
21 focal adhesion kinase, extracellular signal-regulated kinase (ERK)-1/2, p38 mitogen-activated  
22  
23 protein kinase [8, 10]), blocked the expression of enzymes involved in the development and  
24  
25 progression of cancer and inflammation (i.e., cyclooxygenase (COX)-2 (EC 1.14.99.1) and  
26  
27 inducible nitric oxide synthase (iNOS)), and suppressed nuclear factor (NF) $\kappa$ B signalling [8,  
28  
29 10]). However, molecular targets of garcinol are less defined, and thus far, only histone  
30  
31 acetyltransferase p300 (IC<sub>50</sub> = 7  $\mu$ M) [11], P300/CBP-associated factor (IC<sub>50</sub> = 5  $\mu$ M) [11],  
32  
33 and acetylcholine esterase [12] (IC<sub>50</sub> = 0.7  $\mu$ M) were identified.  
34  
35  
36  
37  
38  
39  
40  
41  
42

43  
44 Certain COX-1/2-derived prostanoids and 5-lipoxygenase (5-LO)-derived leukotrienes (LTs)  
45  
46 initiate and maintain inflammatory and allergic reactions (for review see [13]), and  
47  
48 pharmacological intervention with their biosynthesis (i.e., utilizing COX- and 5-LO (EC  
49  
50 7.13.11.34) inhibitors) is applied in therapy of respective diseases. COX-2 and/or 5-LO are  
51  
52 also overexpressed in various cancer cells (e.g., prostate, breast, lung, and colon) [14-16], and  
53  
54 pre-clinical studies indicate tumor-preventive effects of COX inhibition by non steroidal anti-  
55  
56 inflammatory drugs (NSAIDs) [17]. Moreover, pharmacological suppression of the 5-LO  
57  
58 pathway, using 5-LO inhibitors or inhibitors of the 5-LO-activating protein (FLAP), causes  
59  
60  
61  
62  
63  
64  
65

1 apoptosis of various tumor cells [16, 18]. Prostaglandin (PG)E<sub>2</sub> is the most prominent COX  
2 product in inflammation and tumorigenesis and is formed from PGH<sub>2</sub> by PGE<sub>2</sub> synthases. The  
3  
4 microsomal PGE<sub>2</sub> synthase (mPGES)-1 (EC 5.3.99.3) is an inducible isoform functionally  
5  
6 coupled to COX-2. Accumulating evidence suggests that mPGES-1 is responsible for massive  
7  
8 PGE<sub>2</sub> formation associated with pathologies [19]. Therefore, mPGES-1 may represent an  
9  
10 alternative drug target for treatment of inflammation and cancer, which is supported by data  
11  
12 from mPGES-1 deficient mice and animal studies with selective mPGES-1 inhibitors [19-21].  
13  
14  
15  
16  
17  
18

19 Despite the anti-inflammatory and anti-tumorigenic potential of garcinol, its effects on the  
20  
21 formation of eicosanoids were rarely analyzed. Hong et al. recently showed that garcinol  
22  
23 modulates arachidonic acid (AA) metabolism in lipopolysaccharide-stimulated macrophages  
24  
25 by blocking cytosolic phospholipase (cPL)A<sub>2</sub> (EC 3.1.1.4) activation due to inhibition of  
26  
27 ERK1/2-mediated phosphorylation [10]. However, modulation of PG and/or LT biosynthesis  
28  
29 by garcinol or effects on the catalytic activity of the key enzymes involved (e.g., COX-1/2,  
30  
31 PG synthases, 5-LO) have not been addressed yet. Here, we demonstrate that garcinol inhibits  
32  
33 prostanoid and LT formation in cellular and cell-free assays by preferential and potent  
34  
35 interference with mPGES-1 and 5-LO.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## 2. Materials and Methods

### 2.1. Reagents

Garcinol (Biomol, Hamburg, Germany) was dissolved in dimethyl sulfoxide (DMSO) and kept in the dark at -20 °C, and freezing/thawing cycles were kept to a minimum. The thromboxane synthase inhibitor CV4151 [22] and anti-6-keto PGF<sub>1α</sub> antibody were generous gifts by Dr. S. Laufer (University of Tuebingen, Germany) and Dr. T. Dinger mann (University of Frankfurt, Germany), respectively. Materials used: DMEM/High Glucose (4.5 g/l) medium, penicillin, streptomycin, trypsin/EDTA solution, PAA (Coelbe, Germany); PGH<sub>2</sub>, Larodan (Malmö, Sweden); 11β-PGE<sub>2</sub>, PGB<sub>1</sub>, MK-886 (3-[1-(4-chlorobenzyl)-3-*t*-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), 6-keto PGF<sub>1α</sub>, human recombinant COX-2, ovine COX-1, Cayman Chemical (Ann Arbor, MI); [5, 6, 8, 9, 11, 12, 14, 15-<sup>3</sup>H]arachidonic acid ([<sup>3</sup>H]AA), BioTrend Chemicals GmbH (Cologne, Germany); Ultima Gold™ XR, Perkin Elmer (Boston, MA). All other chemicals were obtained from Sigma-Aldrich (Deisenhofen, Germany) unless stated otherwise.

### 2.2. Cells and cell viability assay

A549 cells were cultured in DMEM/High glucose (4.5 g/l) medium supplemented with heat-inactivated fetal calf serum (10%, v/v), penicillin (100 U/ml), and streptomycin (100 µg/ml) at 37 °C in a 5% CO<sub>2</sub> incubator. After 3 days, confluent cells were detached using 1 × trypsin/EDTA solution and reseeded at 2 × 10<sup>6</sup> cells in 20 ml medium in 175 cm<sup>2</sup> flasks. Cell viability was assessed by trypan blue staining and light microscopy. A549 cells (4 × 10<sup>5</sup>) were plated in a 75 cm<sup>3</sup> cell culture flask and incubated at 37 °C and 5% CO<sub>2</sub> for 72 h. Then, garcinol was added and the incubation was continued for 5 or 24 h before cell viability was



1 determined. Treatment with garcinol (10 or 30  $\mu\text{M}$ ) for 5 h did not significantly reduced cell  
2 viability, excluding acute cytotoxic effects in the cellular assays used in this study. However,  
3  
4 prolonged incubation (24 h) with 10 or 30  $\mu\text{M}$  garcinol led to a strong increase in the ratio of  
5  
6 dead cells to total number of cells (50% and 71% dead cells, respectively).  
7  
8  
9

10  
11 Blood cells were freshly isolated from leukocyte concentrates obtained at the Blood Center of  
12  
13 the University Hospital Tuebingen (Germany) as described [23]. In brief, venous blood was  
14  
15 taken from healthy adult donors that did not take any medication for at least 7 days, and  
16  
17 leukocyte concentrates were prepared by centrifugation (4000 $\times$ g, 20 min, 20  $^{\circ}\text{C}$ ). Cells were  
18  
19 immediately isolated by dextran sedimentation and centrifugation on Nycoprep cushions  
20  
21 (PAA, Coelbe, Germany). Platelet-rich-plasma was obtained from the supernatants, mixed  
22  
23 with phosphate-buffered saline (PBS) pH 5.9 (3:2 v/v), centrifuged (2100 $\times$ g, 15 min, room  
24  
25 temperature), and the pelleted platelets were resuspended in PBS pH 5.9/0.9% NaCl (1:1,  
26  
27 v/v). Washed platelets were finally resuspended in PBS pH 7.4 and 1 mM  $\text{CaCl}_2$ . Neutrophils  
28  
29 were immediately isolated from the pellet after centrifugation on Nycoprep cushions, and  
30  
31 hypotonic lysis of erythrocytes was performed as described [24]. Cells were finally  
32  
33 resuspended in PBS pH 7.4 (PBS) containing 1 mg/ml glucose and 1 mM  $\text{CaCl}_2$  (PGC buffer)  
34  
35 (purity > 96-97%).  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **2.3. Release of arachidonic acid in neutrophils**

47  
48  
49  
50

51 Freshly isolated human neutrophils ( $3 \times 10^7/\text{ml}$  PGC buffer) were pre-incubated with the test  
52  
53 compounds for 10 min prior to stimulation with  $\text{Ca}^{2+}$ -ionophore A23187 (2.5  $\mu\text{M}$ ). After 5  
54  
55 min at 37  $^{\circ}\text{C}$ , the reaction was stopped by addition of 1 ml of methanol. After adjusting pH 3  
56  
57 and addition of magarinic acid (11.1 nmol) as internal standard, released AA was separated by  
58  
59 solid phase extraction (RP-18 material and elution with methanol) and coupled to 2,4-  
60  
61  
62  
63  
64  
65

1 dimethoxyaniline hydrochloride (0.14 mg, 0.75  $\mu$ mol) using *N*-Ethyl-*N'*-(3-  
2 dimethylaminopropyl)carbodiimide (1.46 mg, 9.4  $\mu$ mol) as coupling reagent for 1 h at 37 °C.  
3  
4 Derivatized AA was analyzed by RP-HPLC (gradient: 71% methanol / 29% water to 100%  
5 methanol in 20 min, detection at 272 nm).  
6  
7  
8  
9

#### 10 11 12 **2.4. Determination of COX-1 product formation in washed platelets**

  
13  
14  
15

16 Freshly isolated platelets ( $10^8$ /ml PBS containing 1 mM CaCl<sub>2</sub>) were pre-incubated with the  
17 indicated agents for 5 min at room temperature. After addition of 5  $\mu$ M AA and further  
18 incubation for 5 min at 37 °C, the COX-1-derived TxB<sub>2</sub> was quantified using a TxB<sub>2</sub> High  
19 Sensitivity EIA Kit (Assay Designs, Ann Arbor, MI). 12(*S*)-Hydroxy-5-*cis*-8,10-*trans*-  
20 heptadecatrienoic acid (12-HHT, non-enzymatically formed from PGH<sub>2</sub>) was extracted and  
21 analyzed by HPLC as described [23].  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

#### 32 33 34 **2.5. Determination of PGE<sub>2</sub> and 6-keto PGF<sub>1 $\alpha$</sub> formation in intact A549 cells**

  
35  
36  
37

38 Cellular PGE<sub>2</sub> and 6-keto PGF<sub>1 $\alpha$</sub>  formation was determined according to [25]. A549 cells ( $2 \times$   
39  $10^6$  cells) were incubated for 16 h at 37 °C and 5% CO<sub>2</sub>, the medium was changed, and the  
40 cells were stimulated with interleukin-1 $\beta$  (1 ng/ml) for 48 h. After trypsination, cells were  
41 washed with PBS twice. For determination of PGE<sub>2</sub>,  $4 \times 10^6$  cells per ml PBS containing  
42 CaCl<sub>2</sub> (1 mM) were pre-incubated with the indicated compounds at 37 °C for 10 min, and  
43 PGE<sub>2</sub> formation was started by addition of ionophore A23187 (2.5  $\mu$ M), AA (1  $\mu$ M), and  
44 [<sup>3</sup>H]AA (18.4 kBq). The reaction was stopped after 15 min at 37 °C, and the samples were put  
45 on ice. After centrifugation (800 $\times$ g, 5 min, 4 °C), the supernatant was acidified (pH 3) by  
46 addition of citric acid (20  $\mu$ l, 2 M), and the internal standard 11 $\beta$ -PGE<sub>2</sub> (2 nmol) was added.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61 Radiolabeled PGE<sub>2</sub> was separated and analyzed by RP-18 solid phase extraction and HPLC  
62  
63  
64  
65

1 analysis. The amount of  $11\beta$ -PGE<sub>2</sub> was quantified by integration of the area under the eluted  
2 peaks. For quantification of radiolabeled PGE<sub>2</sub>, fractions (0.5 ml) were collected and mixed  
3 with Ultima Gold™ XR (2 ml) for liquid scintillation counting in a LKB Wallac 1209  
4 Rackbeta Liquid Scintillation Counter.  
5  
6  
7  
8  
9

10 For determination of 6-keto PGF<sub>1 $\alpha$</sub> ,  $1 \times 10^6$  cells, resuspended in 1 ml PBS containing CaCl<sub>2</sub>  
11 (1 mM), were pre-incubated with the indicated compounds for 15 min at 37 °C, and 6-keto  
12 PGF<sub>1 $\alpha$</sub>  formation was initiated by addition of AA (30  $\mu$ M). After 15 min at 37 °C, the reaction  
13 was stopped by cooling on ice. Cells were centrifuged (300 $\times$ g, 5 min, 4 °C), and the amount  
14 of released 6-keto PGF<sub>1 $\alpha$</sub>  was assessed by ELISA as described [25].  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

## 27 **2.6. Activity assays of isolated COX-1 and -2**

28  
29  
30  
31 Inhibition of the activities of isolated ovine COX-1 and human COX-2 was performed as  
32 described [25]. Briefly, purified COX-1 (ovine, 50 units) or COX-2 (human recombinant, 20  
33 units) were diluted in 1 ml reaction mixture containing 100 mM Tris buffer pH 8, 5 mM  
34 glutathione, 5  $\mu$ M haemoglobin, and 100  $\mu$ M EDTA at 4 °C and pre-incubated with the test  
35 compounds for 5 min. Samples were pre-warmed for 60 sec at 37 °C, and AA (5  $\mu$ M for  
36 COX-1, 2  $\mu$ M for COX-2) was added to start the reaction. After 5 min at 37 °C, the COX-  
37 derived 12-HHT was extracted and then analyzed by HPLC as described [23].  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 51 **2.7. Preparation of crude mPGES-1 in microsomes of A549 cells and determination of** 52 **PGE<sub>2</sub> synthase activity**

53  
54  
55  
56  
57  
58 Preparation of A549 cells and determination of mPGES-1 activity was performed as described  
59 [25]. In brief, cells were incubated for 16 h at 37 °C and 5% CO<sub>2</sub>, the medium was replaced,  
60  
61  
62  
63  
64  
65

1 interleukin-1 $\beta$  (1 ng/ml) was added and cells were incubated for another 48 h. Cells were  
2 harvested, frozen in liquid nitrogen, and ice-cold homogenisation buffer (0.1 M potassium  
3 phosphate buffer pH 7.4, 1 mM phenylmethanesulphonyl fluoride, 60  $\mu$ g/ml soybean trypsin  
4 inhibitor, 1  $\mu$ g/ml leupeptin, 2.5 mM glutathione, and 250 mM sucrose) was added. After 15  
5 min, cells were sonicated on ice (3  $\times$  20 sec) and the homogenate was subjected to differential  
6 centrifugation at 10,000 $\times$ g for 10 min and 174,000 $\times$ g for 1 h at 4  $^{\circ}$ C. The pellet (microsomal  
7 fraction) was resuspended in 1 ml homogenization buffer and the total protein concentration  
8 was determined by Coomassie protein assay [26]. Microsomal membranes were diluted in  
9 potassium phosphate buffer (0.1 M, pH 7.4) containing 2.5 mM glutathione. Test compounds  
10 or vehicle were added and after 15 min at 4  $^{\circ}$ C, the reaction (100  $\mu$ l total volume) was  
11 initiated by addition of PGH<sub>2</sub> (20  $\mu$ M, final concentration). After 1 min at 4  $^{\circ}$ C, the reaction  
12 was terminated using stop solution (100  $\mu$ l; 40 mM FeCl<sub>2</sub>, 80 mM citric acid, and 10  $\mu$ M of  
13 11 $\beta$ -PGE<sub>2</sub>). PGE<sub>2</sub> was separated by solid phase extraction on reversed phase (RP)-C18  
14 material using acetonitrile (200  $\mu$ l) as eluent and analyzed by RP-HPLC (30% acetonitrile /  
15 70% water + 0.007% TFA (v/v)) with UV detection at 195 nm. 11 $\beta$ -PGE<sub>2</sub> was used as  
16 internal standard to quantify PGE<sub>2</sub> product formation by integration of the area under the  
17 peaks.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **2.8. Determination of PGE<sub>2</sub>, 6-keto PGF<sub>1 $\alpha$</sub> , and 12-HHT formation in human whole** 45 **blood**

46  
47  
48  
49  
50  
51 Peripheral blood from healthy adult volunteers, who had not received any medication for at  
52 least two weeks under informed consent, was obtained by venipuncture and collected in  
53 syringes containing heparin (20 U/ml). For determination of PGE<sub>2</sub> and 6-keto PGF<sub>1 $\alpha$</sub> , aliquots  
54 of whole blood (0.8 ml) were mixed with the thromboxane synthase inhibitor CV4151 (1  $\mu$ M)  
55 and with aspirin (50  $\mu$ M). A total volume of 1 ml was adjusted with sample buffer (10 mM  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

potassium phosphate buffer pH 7.4, 3 mM KCl, 140 mM NaCl, and 6 mM D-glucose). After pre-incubation with the indicated compounds for 5 min at room temperature, the samples were stimulated with lipopolysaccharide (10  $\mu\text{g/ml}$ ) for 5 h at 37  $^{\circ}\text{C}$ . Prostanoid formation was stopped on ice, the samples were centrifuged (2300 $\times$ g, 10 min, 4  $^{\circ}\text{C}$ ), and 6-keto  $\text{PGF}_{1\alpha}$  was quantified in the supernatant using a 6-keto  $\text{PGF}_{1\alpha}$  High Sensitivity EIA Kit (Assay Designs, Ann Arbor, MI) according to the manufacturer's protocol.  $\text{PGE}_2$  was determined as described [25]. In brief, the supernatant was acidified with citric acid (30  $\mu\text{l}$ , 2 M), and after centrifugation (2300 $\times$ g, 10 min, 4  $^{\circ}\text{C}$ ), solid phase extraction, and HPLC, analysis of  $\text{PGE}_2$  was performed to isolate  $\text{PGE}_2$ . The  $\text{PGE}_2$  peak (3 ml), identified by co-elution with the authentic standard, was collected, and acetonitrile was removed under a nitrogen stream. The pH was adjusted to 7.2 by addition of 10  $\times$  PBS buffer pH 7.2 (230  $\mu\text{l}$ ) before  $\text{PGE}_2$  contents were quantified using a  $\text{PGE}_2$  High Sensitivity EIA Kit (Assay Designs, Ann Arbor, MI) according to the manufacturer's protocol.

For determination of 12-HHT, human whole blood (2 ml) was pre-incubated with the indicated compounds at 37  $^{\circ}\text{C}$  for 5 min, and formation of 12-HHT was initiated by addition of 30  $\mu\text{M}$   $\text{Ca}^{2+}$ -ionophore A23187 and 100  $\mu\text{M}$  AA. After 10 min at 37  $^{\circ}\text{C}$ , the reaction was stopped on ice, and the samples were centrifuged (600 $\times$ g/10 min/4  $^{\circ}\text{C}$ ). Aliquots of the resulting plasma (500  $\mu\text{l}$ ) were then mixed with 2 ml of methanol, and 200 ng of  $\text{PGB}_1$  was added as internal standard. The samples were placed at -20  $^{\circ}\text{C}$  for 2 h and centrifuged again (600 $\times$ g/15 min/4  $^{\circ}\text{C}$ ). The supernatants were collected and diluted with 2.5 ml PBS and 75  $\mu\text{l}$  HCl 1 N. Formed 12-HHT was extracted and analyzed by HPLC as described [23].

## 2.9. Expression of human recombinant 5-lipoxygenase in *E.coli*, preparation of homogenates and 100,000 $\times$ g supernatants, and semi-purification of 5-lipoxygenase

**protein**

1  
2  
3  
4 *E.coli* MV1190 was transformed with pT3-5-LO plasmid, and recombinant 5-LO protein was  
5 expressed at 27 °C as described [27]. Cells were lysed in 50 mM triethanolamine/HCl pH 8.0,  
6 5 mM EDTA, soybean trypsin inhibitor (60 µg/ml), 1 mM phenylmethanesulphonyl fluoride,  
7 and lysozyme (500 µg/ml), homogenized by sonication (3 × 15 sec), and centrifuged at  
8 100,000×g for 70 min at 4 °C. The 100,000×g supernatant (S100) was applied to an ATP-  
9 agarose column to partially purify 5-LO as described previously [28]. S100 or semi-purified  
10 5-LO were immediately used for activity assays.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

**2.10. Determination of 5-lipoxygenase product formation in cell-free systems**

22  
23  
24 Aliquots of S100 or semi-purified 5-LO were diluted with ice-cold PBS containing 1 mM  
25 EDTA, and 1 mM ATP was added. Samples were pre-incubated with the test compounds as  
26 indicated. After 10 min at 4 °C, samples were pre-warmed for 30 sec at 37 °C, and 2 mM  
27 CaCl<sub>2</sub> plus 20 µM AA was added to start 5-LO product formation. The reaction was stopped  
28 after 10 min at 37 °C by addition of 1 ml ice-cold methanol, and the formed metabolites were  
29 analyzed by RP-HPLC as described [24]. 5-LO products include the all-trans isomers of LTB<sub>4</sub>  
30 and 5(*S*)-hydro(pero)xy-6-*trans*-8,11,14-*cis*-eicosatetraenoic acid.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

**2.11. Determination of 5-lipoxygenase product formation in intact cells**

45  
46  
47 Freshly isolated neutrophils (5 × 10<sup>6</sup>/ml PGC buffer) were pre-incubated with the test  
48 compounds for 15 min at room temperature and 5-LO product formation was started by  
49 addition of 2.5 µM ionophore A23187 plus 20 µM AA. After 10 min at 37 °C, the reaction  
50 was stopped with 1 ml of methanol and 30 µl of 1 N HCl, and then, 200 ng PGB<sub>1</sub> and 500 µl  
51 PBS were added. Formed 5-LO metabolites were extracted and analyzed by HPLC as  
52 described [24]. 5-LO products include LTB<sub>4</sub> and its all-trans isomers, and 5(*S*-  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1 hydro(pero)xy-6-*trans*-8,11,14-*cis*-eicosatetraenoic acid. Cysteinyl-LTs C<sub>4</sub>, D<sub>4</sub>, and E<sub>4</sub> were  
2 not detected, and oxidation products of LTB<sub>4</sub> were not determined.  
3  
4  
5

## 6 7 **2.12. Statistics** 8

9  
10  
11 Data are expressed as mean ± S.E. IC<sub>50</sub> values are approximations determined by graphical  
12 analysis (linear interpolation between the points between 50% activity). The program  
13 Graphpad Instat (Graphpad Software Inc., San Diego, CA) was used for statistical  
14 comparisons. Statistical evaluation of the data was performed by one-way ANOVAs for  
15 independent or correlated samples followed by Tukey HSD post-hoc tests. A P value of <0.05  
16 (\*) was considered significant.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

### 3. Results

#### 3.1. Effects of garcinol on arachidonic acid release from human neutrophils

Previously, it was suggested that garcinol interferes with eicosanoid formation at the level of gene expression (COX-2) [8], or ERK1/2 phosphorylation resulting in reduced AA release in lipopolysaccharide-stimulated RAW264.7 murine macrophages [10]. We investigated the effects of garcinol on cellular cPLA<sub>2</sub>-mediated AA release in human neutrophils using the Ca<sup>2+</sup>-ionophore A23187 as stimulus that acts by substantial elevation of [Ca<sup>2+</sup>]<sub>i</sub>, independent of cellular signalling pathways. Neutrophils, pre-incubated with garcinol (3 to 33 μM), were stimulated with Ca<sup>2+</sup>-ionophore (2.5 μM), and the released AA was derivatized with 2,4-dimethoxyaniline and analyzed by RP-HPLC. Garcinol failed to significantly suppress the release of AA up to 33 μM (**Fig. 1B**), whereas the cPLA<sub>2</sub>α-inhibitor (control) potently inhibited AA liberation.

#### 3.2. Effects of garcinol on cellular prostanoid formation

Next, we investigated the effects of garcinol on the transformation of AA to prostanoids in intact cells. Prostanoid formation was initiated by addition of exogenous AA in order to circumvent endogenous AA supply, and thus, to exclude inhibition of prostanoid formation at the level of PLA<sub>2</sub>-mediated substrate release. For determination of COX-1 inhibition, human platelets were pre-incubated with garcinol (1 to 33 μM), and formation of COX-1-derived TxB<sub>2</sub> and 12-HHT (non-enzymatically formed from PGH<sub>2</sub> in platelets [29]) was initiated by AA (5 μM). Garcinol significantly suppressed TxB<sub>2</sub> (**Fig. 1C**) and 12-HHT (**Fig. 1D**) formation at 10 μM with an IC<sub>50</sub> of 16 and 11 μM, respectively. To investigate inhibition of cellular COX-2 activity, we assessed the formation of PGE<sub>2</sub> and the stable PGI<sub>2</sub> degradation



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

product 6-keto PGF<sub>1α</sub> (as biomarker for PGI<sub>2</sub> formation) in A549 cells. For measuring 6-keto PGF<sub>1α</sub>, higher concentrations of AA (30 instead of 1 μM) were required than for determination of PGE<sub>2</sub> to get detectable amounts of 6-keto PGF<sub>1α</sub> (detection limit: 14 ng/ml at a signal to noise ratio of 3). A contribution of COX-1 can be excluded in interleukin-1β-stimulated A549 cells because COX-1 is neither detectable on the protein nor on the RNA level [30, 31]. COX-2-mediated synthesis of PGE<sub>2</sub> was significantly inhibited at 10 μM with an apparent IC<sub>50</sub> of approx. 10 μM (**Fig. 2A**), whereas the synthesis of 6-keto PGF<sub>1α</sub> was not significantly reduced by garcinol up to 33 μM (**Fig. 2B**). PGE<sub>2</sub> formation is inhibited by garcinol within a narrow concentration range (3 to 10 μM), and higher concentrations of garcinol failed to completely block PGE<sub>2</sub> synthesis. Also MK-886 (33 μM), a mPGES-1 inhibitor, did not interfere with 6-keto PGF<sub>1α</sub> synthesis and failed to entirely suppress PGE<sub>2</sub> formation [25]. In contrast, the COX-2 inhibitor celecoxib (5 μM) efficiently suppressed both formation of PGE<sub>2</sub> (**Fig. 2A**) and 6-keto PGF<sub>1α</sub> (**Fig. 2B**), respectively.

### 3.3. Effects of garcinol on the activity of COX-1/2 in cell-free assays

40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

We determined whether garcinol may directly interfere with the catalytic activity of isolated COX-1 and/or COX-2. The formation of 12-HHT, the major COX-1/2-derived product under the experimental conditions chosen [32], was initiated by addition of AA (5 μM for COX-1, 2 μM for COX-2). Garcinol concentration-dependently and significantly inhibited COX-1-mediated 12-HHT formation at 10 μM with an IC<sub>50</sub> = 12 μM, which is in good agreement with the efficacy in intact platelets (IC<sub>50</sub> = 11 μM, see above). In contrast, COX-2 activity was not significantly reduced up to 33 μM (**Fig. 3A**). Indomethacin (10 μM, for COX-1) and celecoxib (5 μM, for COX-2), used as reference compounds, potently inhibited 12-HHT formation, as expected (**Fig. 3B**).

### 3.4. Effects of garcinol on the activity of mPGES-1

1  
2  
3  
4  
5 Because garcinol failed to inhibit COX-2 in cell-free assays and did not suppress 6-keto  
6  
7 PGF<sub>1 $\alpha$</sub>  synthesis in A549 cells but reduced PGE<sub>2</sub> formation, it appeared reasonable that  
8  
9 garcinol might selectively suppress PGE<sub>2</sub> formation via inhibition of PGE<sub>2</sub> synthases  
10  
11 downstream of COX-2. Microsomal preparations of interleukin-1 $\beta$ -stimulated A549 cells,  
12  
13 used as source of mPGES-1 [33], were pre-incubated with garcinol or vehicle (DMSO) for 15  
14  
15 min, and then, PGE<sub>2</sub> formation was initiated by addition of 20  $\mu$ M PGH<sub>2</sub>. In agreement with  
16  
17 the literature [25, 34], the mPGES-1 inhibitor MK-886 (used as control) inhibited PGE<sub>2</sub>  
18  
19 formation with an IC<sub>50</sub> of 2.1  $\mu$ M (data not shown). Garcinol was slightly superior over MK-  
20  
21 886 and concentration-dependently inhibited PGE<sub>2</sub> formation with an IC<sub>50</sub> of 1.2  $\mu$ M (**Fig.**  
22  
23 **4A**). Decreasing the PGH<sub>2</sub> concentration to 1  $\mu$ M even enhanced the potency of garcinol to  
24  
25 suppress mPGES-1 activity (IC<sub>50</sub> = 0.3  $\mu$ M, **Fig. 4B**) suggesting a substrate competitive  
26  
27 inhibitory mechanism.  
28  
29  
30  
31  
32  
33  
34  
35

36 To investigate whether garcinol inhibits PGE<sub>2</sub> synthesis in a reversible manner, microsomal  
37  
38 preparations of A549 cells were pre-incubated with garcinol and MK-886, and wash-out  
39  
40 experiments were carried out. MK-886 and garcinol failed to efficiently block PGE<sub>2</sub> synthesis  
41  
42 at 0.3  $\mu$ M, whereas PGE<sub>2</sub> formation was efficiently inhibited at 3  $\mu$ M (**Fig. 4C**). However,  
43  
44 10-fold dilution of the samples containing 3  $\mu$ M garcinol and MK-886 restored mPGES-1  
45  
46 activity (**Fig. 4C**) implying a reversible mode of inhibition.  
47  
48  
49  
50  
51  
52

### 3.5. Effects of garcinol on prostanoid formation in human whole blood

53  
54  
55  
56  
57  
58 Many potent inhibitors of prostanoid biosynthesis in cell-free assays or in intact isolated cells  
59  
60 lose their efficacy under physiologically relevant conditions such as in whole blood.  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Therefore, we investigated whether garcinol could affect prostanoid biosynthesis also in a human whole blood assay. To assess inhibition of COX-1, freshly drawn human venous blood was pre-incubated with the test compounds or vehicle (DMSO) for 5 min and then treated with  $\text{Ca}^{2+}$ -ionophore plus AA (100  $\mu\text{M}$ ). Formation of 12-HHT, which mainly derives from constitutively expressed COX-1 under these experimental conditions, was not significantly affected by garcinol up to 33  $\mu\text{M}$  (**Fig. 5A**). In control experiments, indomethacin (20  $\mu\text{M}$ ) almost completely blocked 12-HHT synthesis.

For determination of COX-2 inhibition, heparinized blood was pre-incubated with garcinol or vehicle (5 min) and stimulated with lipopolysaccharide for 5 h. Then, the levels of  $\text{PGE}_2$  and 6-keto  $\text{PGF}_{1\alpha}$  were determined in the corresponding plasma by ELISA. For measuring  $\text{PGE}_2$  levels,  $\text{PGE}_2$  was first separated from other AA metabolites by RP-HPLC [25]. In agreement with the results obtained with A549 cells, garcinol suppressed  $\text{PGE}_2$  formation in whole blood in a concentration-dependent manner starting at 3  $\mu\text{M}$  with an apparent  $\text{IC}_{50}$  value of 30  $\mu\text{M}$  (**Fig. 5B**). Significant inhibition of  $\text{PGE}_2$  formation was only reached at 30  $\mu\text{M}$  for both garcinol and the mPGES-1 reference inhibitor MK-886, and also prolonged stimulation of whole blood with LPS up to 24 h did not increase the potency of garcinol. Neither garcinol nor MK-886 reduced 6-keto  $\text{PGF}_{1\alpha}$  formation up to 30  $\mu\text{M}$  under the same conditions, suggesting a selective interference of garcinol with  $\text{PGE}_2$  synthesis (**Fig. 5C**). Note that garcinol as well as MK-886 were less efficient in inhibiting  $\text{PGE}_2$  formation as compared to indomethacin or celecoxib.

### 3.6. Inhibition of 5-lipoxygenase product formation by garcinol

To determine the effects of garcinol on 5-LO product formation in intact cells, freshly isolated human neutrophils were pre-incubated with garcinol for 15 min and 5-LO product synthesis

1 was initiated by Ca<sup>2+</sup>-ionophore A23187 (2.5 μM) plus exogenous AA (20 μM). 5-LO  
2 product formation was concentration-dependently inhibited by garcinol with an IC<sub>50</sub> = 1.9 μM  
3  
4 (**Fig. 6A**). Differences in the potency of garcinol to inhibit the formation of LTB<sub>4</sub> (formed via  
5 LTA<sub>4</sub> hydrolase) and 5(*S*)-hydro(pero)xy-6-*trans*-8,11,14-*cis*-eicosatetraenoic acid (IC<sub>50</sub> = 1.5  
6 and 1.8 μM, respectively) were not observed, excluding an interference of garcinol with LTA<sub>4</sub>  
7 hydrolase at these concentrations. The efficiency of garcinol was somewhat improved in a  
8 cell-free assay using 100,000×g supernatant of homogenized neutrophils as source of enzyme  
9 (IC<sub>50</sub> = 0.5 μM, **Fig. 6B**) and was even higher for semi-purified recombinant 5-LO (IC<sub>50</sub> = 0.1  
10 μM, **Fig. 6C**). In contrast, the iron-ligand type 5-LO inhibitor BWA4C (1 μM, used as  
11 control) was equally effective independent of the assay conditions (data not shown).  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

#### 4. Discussion

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Animal studies have revealed an anti-carcinogenic potential of garcinol [2, 3], and *in vitro* studies have demonstrated potent growth-inhibitory and apoptotic [5, 6] as well as anti-oxidant [4] and anti-inflammatory effects [8, 10]. Interference with lipopolysaccharide-induced NF $\kappa$ B signalling, lowering COX-2 and iNOS expression, may explain the long-term anti-inflammatory and anti-carcinogenic effects of garcinol [8], whereas the short term effects were ascribed to impaired cPLA<sub>2</sub> activation through inhibition of ERK-1/2 phosphorylation restricting the supply of AA for eicosanoid formation [10]. Although suppression of eicosanoid formation may be a crucial mode of action of garcinol, direct inhibitory effects on enzymes involved in eicosanoid biosynthesis have not been investigated yet.

Our data demonstrate that garcinol is a direct and potent inhibitor of purified 5-LO and cell-free mPGES-1 with IC<sub>50</sub> = 0.1 and 0.3  $\mu$ M, respectively, and also a direct inhibition of COX-1 by garcinol is evident. Inhibition of other molecular targets (i.e., histone acetyltransferase p300 [11], P300/CBP-associated factor [11], and acetylcholine esterase [12]) required higher concentrations of garcinol (IC<sub>50</sub> = 0.7 to 7  $\mu$ M). However, because of the different experimental settings applied for analysis of the interference of garcinol with these targets, direct comparison of garcinol's potencies is difficult. 5-LO and mPGES-1 are crucial enzymes in the biosynthesis of key mediators in inflammatory processes [16, 19], providing a rationale for the anti-inflammatory effects of garcinol. Moreover, 5-LO and mPGES-1 are overexpressed in many tumors, and PGE<sub>2</sub> as well as 5-LO products play important roles in tumorigenesis [16, 18, 19]. Together, we conclude that the interference of garcinol with 5-LO and mPGES-1 provides a molecular basis for its documented anti-carcinogenic and anti-inflammatory properties.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Inhibition of 5-LO and mPGES-1 is evident also in intact cell assays and in human whole blood. On the other hand, inhibition of COX-1-derived 12-HHT formation in human whole blood was minute and not significant up to 33  $\mu\text{M}$ , although COX-1 activity is obviously inhibited in intact platelets and in the cell-free assay ( $\text{IC}_{50} = 11$  and  $12 \mu\text{M}$ , respectively). This loss of potency in whole blood might be related to albumin-binding of garcinol but also to competition with high AA concentrations (that are required in whole blood for analysis of 12-HHT formation) for binding to the active site of COX-1.

The experimental settings (stimuli used, availability of respective substrates, and products determined) of these cell-based assays allowed us to attribute the effects of garcinol to the interference with the putative targets and to exclude other points of attack. In particular, garcinol may simply block the supply of AA by interference with cPLA<sub>2</sub> activity, an enzyme, whose activation and cellular functionality has been previously proposed to be affected by garcinol [10]. Hong et al. showed that in lipopolysaccharide-stimulated RAW264.7 murine macrophages garcinol blocked AA release by impairing the activation of cPLA<sub>2</sub>. This was ascribed to the interference with defined signalling steps (i.e., ERK signalling, phosphorylation of cPLA<sub>2</sub>) [10]. To circumvent such signalling pathways for cPLA<sub>2</sub> activation, we challenged human neutrophils with the Ca<sup>2+</sup>-ionophore A23187, where the massive increase in intracellular Ca<sup>2+</sup> essentially stimulates cPLA<sub>2</sub>. Garcinol failed to block AA liberation under these experimental conditions, indicating that PLA<sub>2</sub>-mediated AA release is not generally inhibited by garcinol. Note that in our cell-based assays analyzing AA transformations by COX-1/2 or by 5-LO, AA was exogenously supplemented to avoid effects on eicosanoid formation due to inhibition of PLA<sub>2</sub>. On the other hand, the effects of garcinol on PGE<sub>2</sub> and 6-keto PGF<sub>1 $\alpha$</sub>  formation in whole blood were analyzed under conditions (lipopolysaccharide challenge) where AA was supplied by endogenous sources. In contrast to PGE<sub>2</sub> formation, the synthesis of 6-keto PGF<sub>1 $\alpha$</sub>  was unaffected by garcinol, excluding general

1 suppression of AA and suggesting PGE<sub>2</sub> synthase (i.e., mPGES-1) as molecular target of  
2 garcinol. However, our data cannot exclude that garcinol also inhibits other PGE<sub>2</sub> synthases  
3  
4 (such as cytosolic PGE<sub>2</sub> synthase or mPGES-2) in addition to mPGES-1.  
5  
6  
7  
8

9 PGE<sub>2</sub> and 6-keto PGF<sub>1α</sub> are synthesized via the COX-2 pathway in lipopolysaccharide-  
10 stimulated whole blood [35]. Because 6-keto PGF<sub>1α</sub> formation in whole blood was unaffected  
11  
12 by garcinol, our data imply that garcinol-mediated suppression of PGE<sub>2</sub> synthesis in the same  
13  
14 assay is independent of an interference with COX-2. Also, garcinol failed to inhibit isolated  
15  
16 COX-2. Co-expression studies have revealed a preferred functional coupling of COX-2 and  
17  
18 mPGES-1 [36] suggesting that mPGES-1 is the major contributing PGE<sub>2</sub> synthase for PGE<sub>2</sub>  
19  
20 synthesis in lipopolysaccharide-stimulated blood. Nevertheless, in analogy to other mPGES-1  
21  
22 inhibitors [25], garcinol failed to completely suppress PGE<sub>2</sub> synthesis in whole blood and the  
23  
24 remaining PGE<sub>2</sub> synthesis of approx. 40% might be attributable to other PGE<sub>2</sub> synthases (i.e.,  
25  
26 cytosolic PGE<sub>2</sub> synthase or mPGES-2) [25].  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 For inhibition of purified 5-LO (IC<sub>50</sub> = 0.1 μM) and cellular 5-LO product formation (IC<sub>50</sub> =  
37  
38 1.9 μM), a discrepancy in the potencies of garcinol was obvious. Interestingly, a similar  
39  
40 pattern was found for the structurally related hyperforin [23] that possesses an unique  
41  
42 inhibitory mode of action by interfering with the membrane-binding region of 5-LO's C2-like  
43  
44 domain (Feißt et al., 2009, manuscript submitted). However, garcinol is an effective  
45  
46 antioxidant [4] and may act as redox-type inhibitor of 5-LO reducing the active site iron. Such  
47  
48 reduction might be more vigorous for cell-free 5-LO as compared to intracellular enzyme, a  
49  
50 common phenomenon observed for many redox-active 5-LO inhibitors [37].  
51  
52  
53  
54  
55  
56  
57

58 Despite the obvious inhibition of PGE<sub>2</sub> and LT formation by garcinol *in vitro*, the question  
59  
60 whether the interference of garcinol with mPGES-1 and 5-LO accounts for its anti-  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

inflammatory and anti-tumorigenic properties *in vivo*, can not be clearly answered yet. Unpublished studies, mentioned by Hong et al. [10], showed that garcinol inhibited phorbol myristate acetate-induced mouse ear edema accompanied by decreased PGE<sub>2</sub> and LTB<sub>4</sub> production. Of interest, in these experiments the peak plasma levels of garcinol (12 μM) obtained after oral application of garcinol were in a concentration range, where cellular inhibition 5-LO and mPGES-1 is evident in our study. Therefore, one may speculate that garcinol, after oral administration, could achieve plasma levels sufficient to markedly suppress PGE<sub>2</sub> and LT biosynthesis under inflammatory conditions. PGE<sub>2</sub> is one of the most-established key players in the initiation and progression of inflammation [38], and NSAIDs exert their beneficial effects *in vivo* essentially by repressing PGE<sub>2</sub> formation [13]. Animals deficient in COX-2 or mPGES-1 clearly show reduced inflammatory symptoms [19, 39]. Moreover, LTB<sub>4</sub> is a potent chemotactic and chemokinetic agent that recruits pro-inflammatory cells towards sites of inflammation [40]. But also tumorigenesis, particularly of colon, breast, prostate, and lung carcinoma has been associated with excessive PGE<sub>2</sub> and LT formation [16,18,19]. COX-2 selective inhibitors have shown a chemopreventive potential [41], and mPGES-1 is overexpressed in various cancers such as non-small cell lung cancer, invasive breast cancer, colorectal cancer, and gastric cancer [19]. Also 5-LO and its helper-protein FLAP are overexpressed in cancer cells, and 5-LO products promote cell proliferation and/or inhibit apoptosis, whereas 5-LO or FLAP inhibitors caused cell death [18].

In conclusion, we have identified human mPGES-1 and 5-LO as molecular targets of garcinol, and we showed that garcinol potently interferes with the catalytic activity of these enzymes in cell-free and cell-based assays. Inhibition of mPGES-1 and 5-LO may contribute to the anti-carcinogenic and anti-inflammatory effectiveness of garcinol observed in previous studies. Our data indicate that garcinol exerts a promising pharmacological profile combining potent inhibition of PGE<sub>2</sub> and LT formation without marked inhibition of COX isoenzymes.



## References

- 1  
2  
3  
4  
5 [1] Krishnamurthy N, Lewis YS, Ravindranath B. On the structures of garcinol,  
6 isogarcinol and camboginol. *Tetrahedron Letters* 1981;22:793-6.  
7  
8  
9  
10 [2] Yoshida K, Tanaka T, Hirose Y, Yamaguchi F, Kohno H, Toida M, et al. Dietary  
11 garcinol inhibits 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats.  
12 *Cancer Lett* 2005;221:29-39.  
13  
14  
15  
16 [3] Tanaka T, Kohno H, Shimada R, Kagami S, Yamaguchi F, Kataoka S, et al.  
17 Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344  
18 rats. *Carcinogenesis* 2000;21:1183-9.  
19  
20  
21  
22 [4] Yamaguchi F, Ariga T, Yoshimura Y, Nakazawa H. Antioxidative and anti-glycation  
23 activity of garcinol from *Garcinia indica* fruit rind. *J Agric Food Chem* 2000;48:180-5.  
24  
25  
26  
27 [5] Hong J, Kwon SJ, Sang S, Ju J, Zhou JN, Ho CT, et al. Effects of garcinol and its  
28 derivatives on intestinal cell growth: Inhibitory effects and autoxidation-dependent  
29 growth-stimulatory effects. *Free Radic Biol Med* 2007;42:1211-21.  
30  
31  
32  
33 [6] Pan MH, Chang WL, Lin-Shiau SY, Ho CT, Lin JK. Induction of apoptosis by  
34 garcinol and curcumin through cytochrome c release and activation of caspases in  
35 human leukemia HL-60 cells. *J Agric Food Chem* 2001;49:1464-74.  
36  
37  
38  
39 [7] Liao CH, Sang S, Ho CT, Lin JK. Garcinol modulates tyrosine phosphorylation of  
40 FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and  
41 Akt survival signaling in human colon cancer cells. *J Cell Biochem* 2005;96:155-69.  
42  
43  
44 [8] Liao CH, Sang S, Liang YC, Ho CT, Lin JK. Suppression of inducible nitric oxide  
45 synthase and cyclooxygenase-2 in downregulating nuclear factor-kappa B pathway by  
46 Garcinol. *Mol Carcinog* 2004;41:140-9.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [9] Matsumoto K, Akao Y, Kobayashi E, Ito T, Ohguchi K, Tanaka T, et al. Cytotoxic benzophenone derivatives from *Garcinia* species display a strong apoptosis-inducing effect against human leukemia cell lines. *Biol Pharm Bull* 2003;26:569-71.
- [10] Hong J, Sang S, Park HJ, Kwon SJ, Suh N, Huang MT, et al. Modulation of arachidonic acid metabolism and nitric oxide synthesis by garcinol and its derivatives. *Carcinogenesis* 2006;27:278-86.
- [11] Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. *J Biol Chem* 2004;279:33716-26.
- [12] Lenta BN, Vonthron-Senecheau C, Weniger B, Devkota KP, Ngoupayo J, Kaiser M, et al. Leishmanicidal and cholinesterase inhibiting activities of phenolic compounds from *Allanblackia monticola* and *Symphonia globulifera*. *Molecules* 2007;12:1548-57.
- [13] Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science* 2001;294:1871-5.
- [14] Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. *Cancer Lett* 2004;215:1-20.
- [15] Gupta S, Srivastava M, Ahmad N, Sakamoto K, Bostwick DG, Mukhtar H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. *Cancer* 2001;91:737-43.
- [16] Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. *Pharmacol Ther* 2006;112:701-18.
- [17] Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? *Lancet Oncol* 2003;4:605-15.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [18] Chen X, Sood S, Yang CS, Li N, Sun Z. Five-lipoxygenase pathway of arachidonic acid metabolism in carcino-genesis and cancer chemoprevention. *Curr Cancer Drug Targets* 2006;6:613-22.
- [19] Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. *Pharmacol Rev* 2007;59:207-24.
- [20] Cote B, Boulet L, Brideau C, Claveau D, Ethier D, Frenette R, et al. Substituted phenanthrene imidazoles as potent, selective, and orally active mPGES-1 inhibitors. *Bioorg Med Chem Lett* 2007;17:6816-20.
- [21] Xu D, Rowland SE, Clark P, Giroux A, Cote B, Guiral S, et al. MF63 {2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)isophthalonitrile}, a selective microsomal prostaglandin E synthase 1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. *J Pharmacol Exp Ther* 2008;326:754-63.
- [22] Kato K, Ohkawa S, Terao S, Terashita Z, Nishikawa K. Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids. *J Med Chem* 1985;28:287-94.
- [23] Albert D, Zundorf I, Dingermann T, Muller WE, Steinhilber D, Werz O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. *Biochem Pharmacol* 2002;64:1767-75.
- [24] Werz O, Burkert E, Samuelsson B, Rådmark O, Steinhilber D. Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. *Blood* 2002;99:1044-52.
- [25] Koeberle A, Siemoneit U, Buehring U, Northoff H, Laufer S, Albrecht W, et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. *J Pharmacol Exp Ther* 2008;326:975-82.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65
- [26] Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:248-54.
- [27] Fischer L, Szellas D, Rådmark O, Steinhilber D, Werz O. Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. *FASEB J* 2003;17:949-51.
- [28] Burkert E, Arnold C, Hammarberg T, Rådmark O, Steinhilber D, Werz O. The C2-like beta-barrel domain mediates the Ca<sup>2+</sup>-dependent resistance of 5-lipoxygenase activity against inhibition by glutathione peroxidase-1. *J Biol Chem* 2003;278:42846-53.
- [29] Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. *Proc Natl Acad Sci U S A* 1974;71:3400-4.
- [30] Asano K, Lilly CM, Drazen JM. Prostaglandin G/H synthase-2 is the constitutive and dominant isoform in cultured human lung epithelial cells. *Am J Physiol* 1996;271:L126-31.
- [31] Thoren S, Jakobsson PJ. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. *Eur J Biochem* 2000;267:6428-34.
- [32] Capdevila JH, Morrow JD, Belosludtsev YY, Beauchamp DR, DuBois RN, Falck JR. The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by glutathione and glutathione peroxidase(s). *Biochemistry* 1995;34:3325-37.
- [33] Jakobsson PJ, Thoren S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. *Proc Natl Acad Sci U S A* 1999;96:7220-5.
- [34] Claveau D, Sirinyan M, Guay J, Gordon R, Chan CC, Bureau Y, et al. Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-

- 1 regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat  
2 adjuvant-induced arthritis model. *J Immunol* 2003;170:4738-44.
- 3  
4 [35] Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Iacobelli S, et al. Biochemical  
5 and pharmacological characterization of the cyclooxygenase activity of human blood  
6 prostaglandin endoperoxide synthases. *J Pharmacol Exp Ther* 1994;271:1705-12.
- 7  
8 [36] Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, Kojima F, et al.  
9 Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated  
10 prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. *J Biol Chem*  
11 2000;275:32783-92.
- 12  
13 [37] Werz O. Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant  
14 origin. *Planta Med* 2007;73:1331-57.
- 15  
16 [38] Smith WL. The eicosanoids and their biochemical mechanisms of action. *Biochem J*  
17 1989;259:315-24.
- 18  
19 [39] Langenbach R, Loftin CD, Lee C, Tiano H. Cyclooxygenase-deficient mice. A  
20 summary of their characteristics and susceptibilities to inflammation and  
21 carcinogenesis. *Ann N Y Acad Sci* 1999;889:52-61.
- 22  
23 [40] Claesson HE, Dahlen SE. Asthma and leukotrienes: antileukotrienes as novel anti-  
24 asthmatic drugs. *J Intern Med* 1999;245:205-27.
- 25  
26 [41] Rao CV, Reddy BS. NSAIDs and chemoprevention. *Curr Cancer Drug Targets*  
27 2004;4:29-42.
- 28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Acknowledgments**

1  
2  
3  
4 The authors thank Bianca Jazzar and Gertrud Kleefeld for expert technical assistance. The  
5  
6 financial support by the Deutsche Forschungsgemeinschaft is acknowledged.  
7  
8  
9

10  
11  
12 *Conflict of Interest Statement:* None declared.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Figure Legends

### Fig. 1. Effects of garcinol on cellular arachidonic acid release and prostanoid formation.

(A) Chemical structure of garcinol. (B) AA release from neutrophils. Neutrophils ( $3 \times 10^7$ /ml PGC buffer) were pre-incubated with the indicated concentrations of garcinol or vehicle (DMSO, w/o) for 10 min. Then, AA release was initiated by  $\text{Ca}^{2+}$ -ionophore ( $2.5 \mu\text{M}$ ). After 5 min at  $37^\circ\text{C}$ , AA was coupled to 2,4-dimethoxyaniline and analyzed by HPLC as described in the experimental section. In the absence of test compounds (100%, control), 180 ng/ml AA were released. cPLA<sub>2</sub> $\alpha$ -inhibitor ( $10 \mu\text{M}$ ) was used as control. (C) TxB<sub>2</sub> and (D) 12-HHT formation in intact platelets. Platelets ( $10^8$ /ml PBS containing 1 mM  $\text{CaCl}_2$ ) were pre-incubated with the indicated concentrations of garcinol or vehicle (DMSO, w/o) for 5 min prior to stimulation with AA ( $5 \mu\text{M}$ ). After another 5 min at  $37^\circ\text{C}$ , the formation of TxB<sub>2</sub> was assessed by ELISA. TxB<sub>2</sub> formed in the absence of test compounds (100%, control) was 360 ng/ml. The formation of 12-HHT was determined by RP-HPLC as described. 12-HHT formed in the absence of test compounds (100%, control) was 290 ng/ml. Indomethacin (Indo,  $10 \mu\text{M}$ ) was used as control. Data are given as mean  $\pm$  S.E.,  $n = 3$ ,  $**p < 0.01$  or  $***p < 0.001$  vs. vehicle (0.1% DMSO) control, ANOVA + Tukey HSD *post-hoc* tests.

### Fig. 2. Effects of garcinol on cellular arachidonic acid release and prostanoid formation.

(A) PGE<sub>2</sub> formation in A549 cells. Interleukin-1 $\beta$ -stimulated A549 cells ( $4 \times 10^6$ /ml) were pre-incubated with garcinol or vehicle (DMSO, w/o) for 10 min, and then,  $2.5 \mu\text{M}$  A23187 plus  $1 \mu\text{M}$  AA and [<sup>3</sup>H]AA (18.4 kBq) were added. After 15 min at  $37^\circ\text{C}$ , formed [<sup>3</sup>H]PGE<sub>2</sub> was analyzed by RP-HPLC and liquid scintillation counting as described. The 100% value corresponds to 30 ng/ml PGE<sub>2</sub>. MK-886 ( $33 \mu\text{M}$ ) and celecoxib (Cele,  $5 \mu\text{M}$ ) were used as

1 controls. **(B)** 6-Keto PGF<sub>1α</sub> formation in A549 cells. Interleukin-1β-stimulated A549 cells (1  
2 × 10<sup>6</sup>/ml) were pre-incubated with the indicated concentrations of garcinol or vehicle  
3 (DMSO) for 15 min prior to addition of 30 μM AA. After 15 min at 37 °C the amount of 6-  
4 keto PGF<sub>1α</sub> was assessed by ELISA as described. The 100% value corresponds to 70 ng/ml 6-  
5 keto PGF<sub>1α</sub>. Indomethacin (Indo, 10 μM) and celecoxib (Cele, 5 μM) were used as control.  
6  
7 Data are given as mean +/- S.E., n = 3, \*p < 0.05, \*\*p < 0.01 or \*\*\*p < 0.001 vs. vehicle (0.1%  
8 DMSO) control, ANOVA + Tukey HSD *post-hoc* tests.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

19 **Fig. 3. Effects of garcinol on the activity of isolated COX-1 and -2.**  
20  
21  
22  
23

24 **(A)** Purified ovine COX-1 (50 units) or **(B)** human recombinant COX-2 (20 units) were added  
25 to a COX reaction mix, containing 5 mM glutathione. After pre-incubation with the test  
26 compounds or vehicle (DMSO, w/o) for 5 min, the reaction was started with 5 μM (COX-1)  
27 or 2 μM (COX-2) AA. After 5 min at 37 °C, the formation of 12-HHT was determined by  
28 RP-HPLC as described. The 100% values correspond to 80 (COX-1) or 70 (COX-2) ng/ml  
29 12-HHT. Indomethacin (Indo, 10 μM) and celecoxib (Cele, 5 μM) were used as controls.  
30  
31 Data are given as mean +/- S.E., n = 3, \*\*p < 0.01, \*\*\*p < 0.001 vs. vehicle (0.1% DMSO)  
32 control, ANOVA + Tukey HSD *post-hoc* tests.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 **Fig. 4. Effects of garcinol on the activity of mPGES-1.**  
47  
48  
49  
50

51 **(A)** Concentration-response curves for garcinol. Microsomal preparations of interleukin-1β-  
52 stimulated A549 cells were pre-incubated with vehicle (DMSO) or the test compounds at the  
53 indicated concentrations for 15 min at 4 °C, and the reaction was started with 20 μM PGH<sub>2</sub>.  
54  
55 After 1 min at 4 °C, the reaction was terminated using a stop solution containing FeCl<sub>2</sub> and  
56 11β-PGE<sub>2</sub> (1 nmol) as internal standard. The 100% value corresponds to 0.8 nmol PGE<sub>2</sub>. **(B)**  
57  
58  
59  
60  
61  
62  
63  
64  
65



1 The potency of garcinol for mPGES-1 inhibition was compared at 1 and 20  $\mu\text{M}$  PGH<sub>2</sub> as  
2 substrate. The amount of PGE<sub>2</sub> was quantified for 1  $\mu\text{M}$  PGH<sub>2</sub> by use of a PGE<sub>2</sub> High  
3 Sensitivity EIA Kit according to the manufacturer's protocol. The 100% value corresponds to  
4 34 pmol PGE<sub>2</sub>. (C) Reversibility of mPGES-1 inhibition by garcinol and MK-886.  
5  
6 Microsomal preparations of interleukin-1 $\beta$ -stimulated A549 cells were pre-incubated with 3  
7  $\mu\text{M}$  inhibitor for 15 min at 4 °C. An aliquot was diluted 10-fold to obtain an inhibitor  
8 concentration of 0.3  $\mu\text{M}$ . For comparison, microsomal preparations were pre-incubated for 15  
9 min with vehicle (DMSO, w/o) or 0.3  $\mu\text{M}$  MK-886 or garcinol, and then, 20  $\mu\text{M}$  PGH<sub>2</sub> was  
10 added (no dilution). All samples were incubated for 1 min on ice, and PGE<sub>2</sub> formation was  
11 analyzed as described by RP-HPLC. Data are given as mean + S.E.,  $n = 2-4$ ,  $*p < 0.05$  or  
12  $***p < 0.001$  vs. vehicle (0.1% DMSO) control, ANOVA + Tukey HSD *post-hoc* tests.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 **Fig. 5. Effects of garcinol on prostanoid formation in human whole blood.**

30  
31  
32  
33  
34 (A) 12-HHT formation. Heparinized whole blood was pre-incubated with garcinol or vehicle  
35 (DMSO, w/o) at the indicated concentrations for 5 min, and AA (100  $\mu\text{M}$ ) and Ca<sup>2+</sup>-  
36 ionophore (30  $\mu\text{M}$ ) were added to induce COX-product formation. After 10 min at 37 °C, 12-  
37 HHT was extracted and analyzed by RP-HPLC as described. The 100% value corresponds to  
38 1.0  $\mu\text{g/ml}$  12-HHT. Indomethacin (Indo, 20  $\mu\text{M}$ ) was used as control. (B, C) Heparinized  
39 human whole blood, treated with 1  $\mu\text{M}$  thromboxane synthase inhibitor and 50  $\mu\text{M}$  aspirin,  
40 was pre-incubated with the indicated concentrations of garcinol or vehicle (DMSO, w/o) for 5  
41 min at room temperature, and then, prostanoid formation was induced by addition of 10  $\mu\text{g/ml}$   
42 lipopolysaccharide. After 5 h at 37 °C, (B) PGE<sub>2</sub> was extracted from plasma by RP-18 solid  
43 phase extraction, separated by RP-HPLC, and quantified by ELISA as described. The 100%  
44 value corresponds to 9 ng/ml PGE<sub>2</sub>. (C) 6-keto PGF<sub>1 $\alpha$</sub>  was directly determined in blood  
45 plasma by ELISA. The 100% value corresponds to 4 ng/ml 6-keto PGF<sub>1 $\alpha$</sub> . MK-886 (30  $\mu\text{M}$ ),  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


1 indomethacin (Indo, 50  $\mu$ M), celecoxib (Cele, 20  $\mu$ M), or vehicle (DMSO) were used as  
2 controls. Data are given as mean  $\pm$  S.E.,  $n = 3-4$ ,  $**p < 0.01$  or  $***p < 0.001$  vs. vehicle  
3 (0.1% DMSO) control, ANOVA + Tukey HSD *post-hoc* tests.  
4  
5  
6  
7  
8

9 **Fig. 6. Inhibition of 5-lipoxygenase activity by garcinol.**


10  
11  
12  
13  
14 (A) Neutrophils ( $5 \times 10^6$  cells/ml) were pre-incubated with the indicated concentrations of  
15 garcinol or vehicle (DMSO) for 15 min. 5-LO product formation was initiated by addition of  
16  
17 2.5  $\mu$ M  $\text{Ca}^{2+}$ -ionophore plus 20  $\mu$ M AA. (B) S100 of *E.coli* lysates expressing human  
18 recombinant 5-LO or (C) semi-purified human recombinant 5-LO were supplemented with  
19 garcinol and 1 mM ATP, and product formation was started by addition of 2 mM  $\text{CaCl}_2$  and  
20  
21 20  $\mu$ M AA. The 100% values correspond to 1.8, 1.3, and 1.4  $\mu$ g/ml 5-LO products for intact  
22 cells, S100, and purified enzyme, respectively. Data are given as mean + S.E.,  $n = 3-6$ ,  $*p <$   
23  
24 0.05,  $**p < 0.01$  or  $***p < 0.001$  vs. vehicle (0.1% DMSO) control, ANOVA + Tukey HSD  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34 *post-hoc* tests.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Fig. 1


A



B



C



D




Fig. 2




Fig. 3




Fig. 4




Fig. 5





Fig. 6





## graphical abstract

